sb 203580 and n(6)-cyclopentyladenosine
sb 203580 has been researched along with n(6)-cyclopentyladenosine in 2 studies
Compound Research Comparison
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (n(6)-cyclopentyladenosine) | Trials (n(6)-cyclopentyladenosine) | Recent Studies (post-2010) (n(6)-cyclopentyladenosine) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 605 | 0 | 62 |
Protein Interaction Comparison
Protein | Taxonomy | sb 203580 (IC50) | n(6)-cyclopentyladenosine (IC50) |
---|---|---|---|
Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.2256 | |
Adenosine receptor A2b | Rattus norvegicus (Norway rat) | 1.16 | |
Adenosine receptor A1 | Homo sapiens (human) | 0.0027 | |
Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 1.16 |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Dickenson, JM; Germack, R | 1 |
Hu, W; Huang, J; Mahavadi, S; Murthy, KS; Sriwai, W | 1 |
Other Studies
2 other study(ies) available for sb 203580 and n(6)-cyclopentyladenosine
Article | Year |
---|---|
Activation of protein kinase B by the A(1)-adenosine receptor in DDT(1)MF-2 cells.
Topics: Adenosine; Androstadienes; Animals; Calcium; Cell Line; Chromones; Cricetinae; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Genistein; Imidazoles; Indoles; Insulin; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Morpholines; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyridines; Receptors, Purinergic P1; Virulence Factors, Bordetella; Wortmannin; Xanthines | 2000 |
Gi-coupled receptors mediate phosphorylation of CPI-17 and MLC20 via preferential activation of the PI3K/ILK pathway.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Animals; Azepines; Calcium; Cells, Cultured; Chromones; Enkephalin, D-Penicillamine (2,5)-; Estrenes; GTP-Binding Protein alpha Subunits, Gi-Go; Imidazoles; Morpholines; Muscle Contraction; Muscle Proteins; Myocytes, Smooth Muscle; Myosin Light Chains; Myosin-Light-Chain Phosphatase; p21-Activated Kinases; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Pyrrolidinones; Rabbits; Receptor, Adenosine A1; Receptor, Muscarinic M2; Receptors, G-Protein-Coupled; Receptors, Opioid, delta; Receptors, Somatostatin; Recombinant Fusion Proteins; RNA, Small Interfering; Signal Transduction; Somatostatin; Transfection | 2006 |